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Basic science meets clinical 
medicine: identification of a 
CD2AP-deficient patient
S Akilesh1, A Koziell2 and AS Shaw1
Recent years have witnessed an explosion of research into the molecular 
basis of glomerular disease resulting in nephrotic- range urinary protein 
leak using both human genetics and animal models. Löwik et al. describe 
the first case report of an early-onset nephrotic syndrome presenting 
in conjunction with a homozygous CD2AP mutation. These data 
demonstrate the convergence between basic and clinical approaches 
and their potential to transform our understanding of the pathogenetic 
mechanisms underlying human glomerular disease.
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significant proteinuria. Moreover, the 
detection of mutations in a number of 
podocyte genes, such as NPHS1 in Finn-
ish-type congenital nephrotic syndrome 
and NPHS2 in familial focal segmental 
glomerulosclerosis (FSGS), has com-
pounded the role of podocyte dysfunction 
in nephrotic-range glomerular proteinu-
ria.1 More recently, mutations of two other 
genes expressed in podocytes, α-actinin-
4 (ACTN4)2 and TRPC6,3,4 have been 
detected in human FSGS (Figure 1).
In parallel with positional cloning 
approaches to identify human genes 
linked to nephrotic syndrome, mouse 
knockout and expression studies have led 
to the identiﬁcation of other molecules 
that may be of equal importance in the 
maintenance of glomerular permselectiv-
ity.5 Some are podocyte speciﬁc, such as 
NEPH1 and synaptopodin, whereas oth-
ers, such as CD2AP, Nck, P-cadherin, and 
FAT1, are more ubiquitously expressed. An 
important immediate goal is to determine 
whether these genes, identiﬁed in mice, are 
relevant to human disease (Figure 1).
Löwik et al.6 (this issue) present a case 
report in which the evaluation of a male 
infant for failure to thrive at the age of 10 
months led to a diagnosis of an early-onset 
nephrotic syndrome. As the child had 
failed to thrive for some time, it is likely 
that the onset of the nephrotic syndrome 
occurred much earlier in life. Salient clini-
cal features at presentation were anemia, 
hypertension, and hypoalbuminemia in 
the context of nephrotic-range proteinu-
ria. Renal function was normal, which is 
perhaps discrepant with the other present-
ing clinical features. Ten glomeruli were 
obtained on renal biopsy, of which almost 
half were globally sclerosed despite the 
normal creatinine. Mesangial prolifera-
tion and matrix expansion were observed 
in the other half, whereas one glomerulus 
was reported as having a lesion compatible 
with collapsing FSGS. No immunohisto-
chemistry is reported, although electron 
microscopy did demonstrate foot process 
fusion. The patient’s renal function dete-
riorated over the next 2 years, with an epi-
sode of acute collapse secondary to sepsis 
precipitating end-stage renal failure about 
2 years after diagnosis. Subsequent renal 
transplantation has not been complicated 
by recurrence of disease.
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The glomerular ﬁltration barrier is a com-
plex structure composed of three layers: 
a fenestrated endothelium, glomerular 
basement membrane, and podocytes, 
modiﬁed epithelial cells with foot proc-
esses separated by specialized junctions 
called slit diaphragms. Breakdown of 
this barrier is thought to be the common 
feature underlying proteinuric diseases. 
During the last decade, there has been 
enormous progress in our understanding 
of how the ﬁltration barrier works. Much 
of this work has focused on the unique 
properties of the podocyte.
Interest in the podocyte began with 
the ﬁnding that the morphology of these 
cells is universally abnormal in all types 
of glomerular disease associated with 
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Assuming the nephrotic syndrome 
presented after 3 months of age, the most 
likely diﬀerential lies between early-onset 
FSGS and infantile diﬀuse mesangial scle-
rosis (DMS), two conditions that are often 
diﬃcult to diﬀerentiate both clinically and 
by renal histology and that are thought 
to lie on a clinicopathological spectrum. 
DMS is the second most common type of 
infantile nephrotic syndrome, developing 
around 1–2 years of age and proceeding 
inexorably toward renal failure. Although 
most cases of DMS are caused by muta-
tions of the transcription factor WT1 and 
are associated with Denys-Drash syn-
drome, about 20% are idiopathic in ori-
gin. In view of the profound anemia and 
hypertension at presentation and lack of 
recurrence of the nephrotic syndrome after 
transplantation, it is tempting to speculate 
that the cause of the nephrotic syndrome 
in the patient described by Löwik et al.6 
may have in fact been DMS. It should be 
noted, however, that renal histological 
analysis of this age group is fraught with a 
quagmire of features that overlap not only 
between FSGS and DMS, but also with 
normal variability in glomerular appear-
ance in early human life.
Sequencing analysis of the CD2AP gene 
in this patient revealed a homozygous 
mutation with a nonsense codon at amino 
acid position 612 leading to a prema-
ture stop and truncation of the encoded 
CD2AP protein 27 amino acids short of 
the C terminus. The truncated protein was 
not detectable on immunoblot in either 
the patient or the heterozygote parents; 
this implicates the extreme C terminus of 
CD2AP in protein stabilization.
CD2AP is a 70-kilodalton protein 
involved in regulation of the actin cytoskel-
eton and intracellular traﬃcking that was 
originally cloned as an interaction partner 
of CD2, a signaling protein expressed on 
the surface of T lymphocytes. In the kid-
ney, CD2AP is expressed in the podocyte, 
proximal tubule, and collecting duct. The 
sensitivity of podocytes to the CD2AP loss 
is probably best explained by the fact that 
podocytes lack expression of CIN85, a 
homologue for CD2AP.
The identif ication of the f irst 
homozygous mutation of CD2AP in a 
human patient validates a growing body of 
work using mouse models to understand 
the function of the ﬁltration barrier. The 
patient’s disease recapitulated some fea-
tures observed in CD2AP-deﬁcient mice. 
In contrast to patients with Finnish-type 
congenital nephrotic syndrome,1,7 CD2AP-
deﬁcient mice are initially asymptomatic 
and ﬁrst develop proteinuria at 3 weeks of 
age, only progressing to renal failure at 6–8 
weeks of age.8 A parallel might be drawn, 
as the pathological features detected in the 
kidney of the patient reported by Löwik 
et al.,6 namely global glomerulosclerosis 
and mesangial expansion, are also detected 
in the kidneys of the CD2AP knockout 
mouse—similarities that help validate a 
role for CD2AP dysfunction in human 
glomerular disease.
As well as the association of murine 
and human nephrotic syndrome with 
homozygous CD2AP mutations, there is 
also evidence to suggest that CD2AP heter-
ozygosity is a risk factor for FSGS.9 As they 
age, CD2AP-heterozygous mice develop 
glomerular changes that resemble FSGS 
but, unlike their homozygous counterparts, 
do not spontaneously develop either neph-
rotic syndrome or renal failure. However, 
increased susceptibility to nephrotoxic 
injury is present in comparison with wild-
type mice. In support of CD2AP heterozy-
gosity also being a risk factor for FSGS in 
humans, mutation screening of 45 patients 
with HIV nephropathy detected a hetero-
zygous exon 7 splice acceptor mutation in 
two cases, absent in matched controls.9 
Analogously to the study by Löwik et al.,6 
this mutation also results in a truncated 
protein that is not expressed, providing 
further corroborative evidence that C-ter-
minal truncations result in destabilization 
of the CD2AP protein. As the parents of 
the reported patient did not have any evi-
dence of proteinuria, it is possible that, as 
in the CD2AP+/– mice, heterozygosity was 
insuﬃcient to produce disease per se, until 
another environmental stressor or second-
ary mutation in a cooperating gene was 
introduced into the equation.
Given the growing number of podocyte 
proteins implicated in both normal and 
abnormal glomerular filtration barrier 
function, it seems likely that many cases 
of glomerular disease may be due to either 
homozygous or heterozygous mutations of 
genes leading to abnormal or absent pro-
tein products or aberrant interactions and 
dysfunctional cellular machinery. Some 
mutations may be signiﬁcant enough to 
impair the normal ﬁltration of the kidney 
on their own, whereas others may simply 
increase disease susceptibility that then 
requires a secondary epigenetic hit or 
Figure 1 | Basic science meets clinical medicine. The study of human patients with renal disease 
has led to the identification of several genes important for the functioning of the glomerular filter. 
Mouse mutants have been generated for three of these genes (NPHS1, NPHS2, and ACTN4) and 
have confirmed the role of these genes in glomerular filtration barrier integrity. For the first time, a 
mutation known to cause nephrotic syndrome in mice (Cd2ap) has also been identified in human 
patients. This finding validates the studies of CD2AP-deficient mice. Several genes that lead to renal 
failure have been identified in mice (Kirrel, Fat1, Synpo, and Nck1), and one has been identified in 
humans (TRPC6). The next step is to validate these genes by identifying patients with mutations 
and by generating knockout mice. The genes identified as contributors to disease are indicated in 
parentheses next to their protein product.
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mutation in another gene for nephrosis to 
manifest. Basic-science approaches provide 
an important means of identifying these 
potential genetic candidates and conse-
quent accurate functional characterization 
of the encoded protein in the context of its 
cellular environment. Moreover, these key 
scientiﬁc building blocks ultimately lead 
to a uniquely focused approach able to 
identify those populations most at risk of 
glomerular disease and the development of 
directed strategies to ameliorate that risk.
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Chronic kidney disease definition 
and classification: the quest for 
refinements
G Eknoyan1
The definition and staging of chronic kidney disease (CKD) have 
provided a unifying approach to CKD that has generated considerable 
new information on the epidemiology, course, outcomes, and 
burden of CKD.  Eriksen and Ingebretsen5 propose a change in the 
current 3 months chronicity criterion of CKD. Whereas longer lengths 
of chronicity changed the number of patients in stages 3 and 4, 
mortality remained high in each of their new groupings.  Essentially, 
CKD persisted and remained a risk multiplier of death.  
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Beginning with Richard Bright’s report of 
cases with end-stage kidneys, and certainly 
after the advent of maintenance dialysis in 
the 1960s, much of the attention of neph-
rology and health agencies focused on 
the cost and treatment of end-stage renal 
disease (ESRD). As data from dialysis reg-
istries accrued in the 1980s, it gradually 
became evident that the mortality of these 
patients was high, principally because of 
coexistent morbidities and the complica-
tions of kidney disease with which they 
presented to dialysis, and that their care 
should have been initiated earlier.
Throughout this period, and well into 
the 1990s, kidney disease was categorized 
by cause (glomerulonephritis, pyelone-
phritis, lupus nephropathy, and so on). 
This traditional taxonomic approach is 
useful when diagnosis determines treat-
ment of a speciﬁc disease. What registry 
data revealed, however, was that most 
ESRD patients presented in kidney failure 
without a previous diagnosis of kidney 
disease, and that the number of cases of 
kidney failure that could be attributed to 
traditional causes was relatively small 
and decreasing, whereas the number due 
to hypertension and diabetes was large 
and increasing, especially in the elderly 
and some ethnic and racial groups. In the 
majority of them, the kidney disease had 
been asymptomatic and escaped detec-
tion, and the complications of the dis-
ease had been established. The question 
of how to identify them early enough to 
treat them became a major concern but 
remained unanswered.
As epidemiologic data on kidney dis-
ease accrued in the 1990s, it became 
evident that the systemic complications 
of progressive loss of kidney function 
(anemia, hypertension, mineral and 
bone disorders, cardiovascular disease) 
were uniform and independent of the 
primary cause of the kidney disease. 
The various terms used to describe the 
commonality of these patients (chronic 
renal failure, pre-dialysis, pre-ESRD, 
azotemic, uremic) were descriptive, ill-
deﬁned, vague, and variably used. This 
ambiguous terminology coupled with 
categorization of patients at diﬀering 
cutoﬀ levels of creatinine resulted in 
data that indicated a large, but variable, 
number of individuals with kidney dis-
ease in the general population.1
In 2002, the National Kidney Founda-
tion’s Kidney Disease Outcomes Qual-
ity Initiative (KDOQI) clinical practice 
guidelines provided for the ﬁrst time 
a working definition of chronic kid-
ney disease (CKD), irrespective of the 
cause of kidney disease, based on the 
presence of either kidney damage or a 
glomerular ﬁltration rate of less than 
60 ml/min/1.73 m2 for more than 3 
months. The guidelines also proposed 
a classiﬁcation system based on sever-
ity determined by the level of kidney 
function, calculated from the estimated 
glomerular ﬁltration rate (eGFR), again 
